Scott A Pratt

US Patent:

7514441, Apr 7, 2009

Filed:

Aug 21, 2003

Appl. No.:

10/525158

Inventors:

Tsuneo Yasuma - Ibaraki, JP
Akira Mori - Kyoto, JP
Masahiro Kawase - Hyogo, JP
Hiroyuki Kimura - Sakai, JP
Masato Yoshida - Sanda, JP
Albert Charles Gyorkos - Westminster CO, US
Scott Alan Pratt - Broomfield CO, US
Christopher Peter Corrette - Arvada CO, US

Assignee:

Takeda Pharmaceutical Company Limited - Osaka

International Classification:

C07D 487/04
A61K 31/519
A61P 19/08
A61P 19/10

US Classification:

5142593, 544281, 544263

Abstract:

There is provided a calcium receptor modulator comprising a compound of the formula (I):.

US Patent:

7714009, May 11, 2010

Filed:

Oct 27, 2004

Appl. No.:

10/577334

Inventors:

Albert Charles Gyorkos - Westminster CO, US
Christopher Peter Corrette - Boulder CO, US
Suk Young Cho - Boulder CO, US
Timothy Mark Turner - Boulder CO, US
Scott Alan Pratt - Boulder CO, US
Kazuyoshi Aso - Osaka, JP
Masakuni Kori - Osaka, JP
Michiyo Gyoten - Osaka, JP

Assignee:

Takeda Pharmaceutical Company Limited - Osaka

International Classification:

A61K 31/4168
C07D 403/12
C07D 403/14
C07D 235/30

US Classification:

514388, 5483061, 5483074

Abstract:

There is provided a CRF receptor antagonist comprising a compound of the formula (I):.

US Patent:

8163935, Apr 24, 2012

Filed:

Apr 26, 2006

Appl. No.:

11/919435

Inventors:

Kazuyoshi Aso - Osaka, JP
Michiyo Mochizuki - Osaka, JP
Albert Charles Gyorkos - Westminster CO, US
Christopher Peter Corrette - Boulder CO, US
Suk Young Cho - Gyeonggi-Do, KR
Scott Alan Pratt - Boulder CO, US
Christopher Stephen Siedem - Boulder CO, US

Assignee:

Takeda Pharmaceutical Company Limited - Osaka

International Classification:

C07D 403/02
C07D 235/24
C07D 235/26
C07D 235/30
A61K 31/415

US Classification:

5483061, 5483064, 5483074, 514395

Abstract:

There is provided a CRF receptor antagonist comprising a compound of the formula (I):.

US Patent:

20090215746, Aug 27, 2009

Filed:

Oct 31, 2008

Appl. No.:

12/263426

Inventors:

Tsuneo Yasuma - Osaka, JP
Akira Mori - Kyoto, JP
Masahiro Kawase - Hyogo, JP
Hiroyuki Kimura - Osaka, JP
Masato Yoshida - Osaka, JP
Albert Charles Gyorkos - Westminster CO, US
Scott Alan Pratt - Broomfield CO, US
Christopher Peter Corrette - Arvada CO, US

Assignee:

Takeda Pharmaceuticals Company Limited - Osaka

International Classification:

A61K 31/519
A61K 31/55
A61K 31/541
A61K 31/5377
C07D 487/10
C07D 487/04
A61P 19/00

US Classification:

51421208, 5142285, 5142332, 51425505, 5142593, 514267, 540524, 544 584, 544231, 544250, 544282

Abstract:

There is provided a calcium receptor modulator comprising a compound of the formula (I):wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; Xis CR, CRR, N or NR; Xis N or NR; Y is C, CRor N, Z is CR, CRR, N or NR; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R, R, R, R, R, R, Rand Rare independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III):wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CRor N; R, R, R, Rand Rare independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided.Also specify X, R, R, Y and Xin formula (II) and (III) as before.

US Patent:

20090286791, Nov 19, 2009

Filed:

Jul 20, 2007

Appl. No.:

12/309493

Inventors:

Shuji Kitamura - Osaka, JP
Thomas Daniel Aicher - Superior CO, US
Steve Gonzales - Media PA, US
Yvan Le Huerou - Boulder CO, US
Scott Alan Pratt - Longmont CO, US
Tim Turner - Longmont CO, US
Yoshihisa Nakada - Osaka, JP

Assignee:

TAKEDA PHARMACEUTICAL COMPANY LIMITED - OSAKA

International Classification:

A61K 31/4155
C07D 401/12
C07D 403/12
C07D 413/14
C07D 231/14
A61P 3/04
A61P 3/10
A61K 31/4439
A61K 31/4184
A61K 31/498
A61K 31/497
A61K 31/5377
A61K 31/506

US Classification:

5142365, 5462754, 5483061, 544405, 544355, 544131, 5462757, 5462734, 5483741, 514341, 514394, 514249, 51425505, 514273, 514406

Abstract:

The present invention provides compounds represented by the formula (Ia):the formula (Ib):the formula (Ic):and the formula (Id):wherein each symbol is as defined in the specification.According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

US Patent:

20100056515, Mar 4, 2010

Filed:

Oct 24, 2007

Appl. No.:

12/312087

Inventors:

Kazuyoshi Aso - Osaka-shi, JP
Michiyo Mochizuki - Osaka-shi, JP
Takuto Kojima - Osaka-shi, JP
Katsumi Kobayashi - Osaka-shi, JP
Scott Alan Pratt - Longmont CO, US
Albert Charles Gyorkos - Westminster CO, US
Christopher Peter Corrette - Arvada CO, US
Suk Young Cho - Gyeonggi-Do, KR

International Classification:

A61K 31/5377
A61K 31/4412
A61K 31/4166
C07D 413/10
C07D 401/12
C07D 235/26
A61P 25/24
A61P 25/22

US Classification:

5142345, 514338, 514395, 544139, 5462737, 5483064

Abstract:

There is provided a compound of the formula (I):wherein Ris an optionally substituted Calkyl; Ris H, or a Calkyl which may be substituted with 1 to 3 substituents; Ris a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6-membered ring which may be substituted with 1 to 3 Calkyls; Ris a hydrogen, a halogen, a hydroxy, a cyano, a Calkyl or a Calkoxy; Z is —O—, —S—, —SO—, —SO—, or —NR— wherein Ris a hydrogen or a Calkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.

US Patent:

20120065196, Mar 15, 2012

Filed:

Jul 20, 2007

Appl. No.:

12/309480

Inventors:

Shuji Kitamura - Osaka, JP
Thomas Daniel Aicher - Superior CO, US
Steve Gonzales - Media PA, US
Yvan Le Huerou - Boulder CO, US
Scott Alan Pratt - Longmont CO, US
Yoshihisa Nakada - Osaka, JP

International Classification:

A61K 31/541
A61K 31/454
A61K 31/445
C07D 401/12
C07D 413/12
A61K 31/4245
C07D 513/00
A61K 31/428
A61K 31/497
C07D 403/12
A61K 31/5377
C07D 417/12
A61P 3/04
A61P 3/10
A61P 3/06
C07D 401/06

US Classification:

5142278, 546210, 514326, 514318, 546208, 548144, 514364, 548132, 548153, 514367, 51425405, 544371, 544140, 5142365, 544 582

Abstract:

The present invention provides compounds represented by the formula (Ie):and the formula (If):wherein each symbol is as defined in the specification.According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

US Patent:

20130158009, Jun 20, 2013

Filed:

May 13, 2011

Appl. No.:

13/698257

Inventors:

Thomas Daniel Aicher - Boulder CO, US
Josef Roland Bencsik - Boulder CO, US
Kevin Ronald Condroski - Boulder CO, US
Jay Bradford Fell - Boulder CO, US
John P. Fischer - Boulder CO, US
Ronald Jay Hinklin - Boulder CO, US
Scott Alan Pratt - Boulder CO, US
Ajay Singh - Boulder CO, US
Timothy M. Turner - Boulder CO, US
Steven Armen Boyd - Boulder CO, US

International Classification:

C07D 413/14
C07D 405/14
C07D 401/14

US Classification:

51421208, 544409, 51425505, 544336, 544332, 514275, 546194, 514318, 544321, 514273, 544331, 544238, 51425203, 546187, 514316, 544405, 540524

Abstract:

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X, X, L, R, R, R, R, R, R, R, R, and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.